Healthcare >> CEO Interviews >> August 25, 2003
DAVID W. CARTER is Chairman and Chief Executive Officer of Xenogen
Corporation. Prior to joining Xenogen, Mr. Carter was Chairman of the
Board, President and Chief Executive Officer of Somatix Corporation, a
publicly held gene therapy company. In this capacity he completed a
number of public and private financings, corporate partnerships and
acquisitions. The most recent of these activities was the successful
merger of Somatix with Cell Genesys into a gene therapy powerhouse with
a market cap of over $500 million. Mr. Carter has held executive
management positions at several other companies including: President and
Chief Operating Officer of Northfield Laboratories, a company involved
in developing a hemoglobin substitute; Executive Vice President of
Sybron Corporation, a $650 million life science corporation; and Group
President with American Hospital Supply Corporation. Mr. Carter also
serves on the Board of Directors for ImmunoGen, Inc., Cell Genesys and
Ceregen, Inc. Profile
Corporation and a picture of the things you're doing at the present
time?
Mr. Carter: The company was founded in 1995 by three
